Trident Lifeline Q2 FY27: consolidated revenue +50% YoY, PAT +33%, margin compresses
PAT +33.31% YoY · revenue +50.25% · margins compressing
₹47.08 Cr
+50.25% YoY
₹6.6 Cr
+33.31% YoY
13.73%
-0.2pp YoY
₹5.69
Trident Lifeline's consolidated (primary basis) revenue rose 50.2% YoY to ₹47.08 Cr (Q2 FY26: ₹31.34 Cr, corroborated by external reporting of ₹31.42 Cr) and 39.6% sequentially from ₹33.72 Cr in Q1 FY27. Consolidated PAT (after minority interest) grew 33.3% YoY to ₹6.60 Cr from ₹4.95 Cr, and 31.1% QoQ from ₹5.03 Cr, with basic EPS at ₹5.69 versus ₹4.27 a year ago. No exceptional or extraordinary items were booked in either the current or comparative periods, so these are reported, like-for-like growth numbers — there is no analyst/street estimate available for this SME-platform microcap to grade the print against, and management has issued no formal prior guidance on record, so neither vs-street nor vs-guidance can be assessed.
Q2 FY-2027 vs prior quarters
The bottom line grew slower than the top line because net margin compressed even as operating margin expanded: consolidated OPM improved to roughly 24.1% from ~21.9% a year ago, but NPM fell to 13.7% from ~15.0% YoY (and from 14.7% in Q1 FY27). The gap sits below the operating line — financial costs nearly doubled YoY to ₹1.93 Cr (from ₹0.99 Cr) and depreciation rose 71% to ₹1.56 Cr (from ₹0.91 Cr), consistent with debt-funded capacity expansion: consolidated long-term borrowings climbed to ₹67.96 Cr from ₹40.03 Cr at FY26-end, and capital work-in-progress rose to ₹21.02 Cr from ₹17.50 Cr.
The stock went into the print at ₹418.95, up 4.2% over the past month of trading.
For context: PAT has now risen for 2 consecutive quarters.
The standalone (parent-only) print tells a different story and materially diverges from consolidated: standalone revenue fell 29.3% YoY to ₹32.73 Cr and standalone PAT fell 21.9% YoY to ₹6.58 Cr, implying the group's growth is coming from subsidiaries (TNS Pharma, TLL Parenterals, Trident Mediquip, TLL Elements, TLL Wellness) rather than the parent entity itself — readers comparing the standalone number elsewhere should not read it as contradicting the consolidated growth story. Alongside the results, the board declared a first interim dividend of ₹0.50/share (record date October 30, 2026), the company allotted 24,000 equity shares on warrant conversion and approved a fresh preferential issue of shares and warrants, and subsidiary Trident Mediquip's private placement (October 15, after quarter-end) diluted the parent's stake to 58.23% from 59.67% at quarter-end — continued external capital-raising running alongside the debt-funded capex. No management press release accompanied this filing, so there is no qualitative commentary from the company on the quarter's drivers to cross-check against the numbers.
W1
Financial costs (₹1.93 Cr this quarter, +95% YoY) and depreciation (₹1.56 Cr, +71% YoY) trajectory as the debt-funded capacity expansion (CWIP ₹21.02 Cr, long-term debt ₹67.96 Cr) continues — watch for further net-margin pressure even if OPM holds
W2
Minority interest/PAT attribution impact from Trident Mediquip's stake dilution to 58.23% (private placement, Oct 15, after quarter-end) in the next consolidated print
W3
Whether standalone revenue (-29.3% YoY to ₹32.73 Cr this quarter) keeps shrinking as more business shifts to the subsidiaries driving consolidated growth
Figures sourced from the Quarter Ended tables (CY Q2 column, 30.09.2026) in both standalone and consolidated P&L statements; original unit Lacs, divided by 100 for Cr. No exceptional/extraordinary items in current or comparative periods. Minority interest is negligible (₹0.08 L, negative, i.e. minority loss). Our internal DB 'year-ago quarter' comparison record (revenue ₹53.36 Cr, PAT ₹7.875 Cr, EPS ₹6.91, OPM 5.72%) does not match either the filing's own restated PY Q2 comparative (₹31.34 Cr revenue, ₹4.95 Cr PAT, EPS ₹4.27) or the externally reported Q2 FY26 actuals (₹31.42 Cr revenue, ₹4.95 Cr PAT per IndMoney) — treated as stale/incorrect and NOT used; YoY figures below use the filing's own, externally-corroborated comparative instead. Standalone and consolidated diverge materially (standalone revenue -29.3% YoY vs consolidated +50.2% YoY) — flagged per basis rule.